Reports

Drug name	NICE TAs	Comments
Encorafenib (Braftovi®)	TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Encorafenib with binimetinib	TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entrectinib	TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide capsules	TA377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide capsules#8.3	TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer	For hospital use only
Epirubilin solution for injection	TA250 - Eribulin for the treatment of locally advanced or metastatic breast cancer TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Epoetin beta syringe (Neorecormon)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG Commissioned for use in cancer - NICE TA323.
Eptifibatide injection	TA47 - Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes	Hospital use only
Erlotinib tablets	TA162 - Erlotinib for the treatment of non-small-cell lung cancer TA374 - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy TA258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer TA295 - Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy
Ertugliflozin (Steglatro®)	TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports